News AZ sells US, EU and Latin America rights to gout drug AZ focused on sales target set by CEO Pascal Soriot.
Articles NICE and Highly Specialised Technologies: three years on Leela Barham examines the process for the appraisal of Highly Specialised Technologies.
Articles The UK pharma market – Accelerating Access or still stuck in... Hundreds of novel medicines are expected to gain approval between 2016 and 2020 but will the NHS make the most of the best new drugs, or limit access and uptake as in previous years?
News Caribou gains $30m funding for CRISPR-Cas platform Genetic engineering specialist Caribou Biosciences has secured $30 million in a series B funding round.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
